Carrington Reports on ISO 9001:2000 Inspection at Sablila Industrial in Costa Rica
September 27, 2007 (PRLEAP.COM) Health NewsCarrington Laboratories, Inc. (OTC: CARN) announced that its bulk pharmaceutical manufacturing subsidiary, Sábila Industrial, S.A., located in Liberia, Guanacaste, Costa Rica, has completed an annual ISO 9001:2000 re-certification inspection by the European Union’s notified body, AENOR Internacional, S.A.U. of Madrid, Spain.
Mr. José Zúñiga, Carrington’s vice president of operations and manager of South American business, stated, "The Chief Inspector representing AENOR Internacional stated that this is the first time any company audited by his team has performed at such a high quality level that no nonconformances with ISO quality systems have been found over a two-year period. We at Carrington, and in particular Sábila Industrial, are delighted that our quality systems are recognized by an EU’s notified body. We credit our frequent quality audits in Costa Rica and at our manufacturing facilities in Texas as key to our success."
Mr. Zúñiga added, "Using organic certified plant materials, our Costa Rica plant manufactures the GelSite® polymer, the raw material key to the drug and vaccine delivery technology being developed by Carrington’s biotech subsidiary DelSite Biotechnologies, Inc. GelSite® is used to make the influenza nasal powder vaccine for bird flu (H5N1). Additionally, our corporate site in Texas uses organic methods on its grounds, our Costa Rica farming operation is certified organic, and our raw material Manapol® is kosher certified. These certifications and quality systems are not inexpensive, but they show our dedication to quality. These inspection results let our customers and potential customers know that, as a corporation, we are dedicated to developing, implementing, and maintaining the highest quality standards for the protection of those who use our raw materials and finished products."
About Sábila Industrial:
Sábila Industrial, S.A. is a wholly owned subsidiary of Carrington Laboratories, Inc. dedicated to producing raw materials for oral care, wound care, and consumer products manufactured by Carrington and GelSite® for DelSite Biotechnologies, Inc. All naturally derived polymeric raw materials are produced under the FDA’s cGMP standards for use in human drugs. An injectable biologic raw material to treat fibrosarcoma in companion animals is produced by Sábila under USDA biologic regulations. Sábila Industrial, S.A. operates in a duty-free zone with an adjacent farm, Finca Sábila, which is certified organic by an agency of the Costa Rican government and recognized by the USDA and the European Union.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol® and cosmetic raw material Hydrapol™. Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington’s DelSite Biotechnologies subsidiary is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission.